Omar Perbellini
Vicenza, 36100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.
Journal: Cancers
Published: January 08, 2026
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.
Journal: The New England journal of medicine
Published: December 30, 2025
Improved Detection of Minimal Residual Disease in AML: Validation of IDH1/2 ddPCR Assays in the Perspective of Treatment with Target Inhibitors.
Journal: International journal of molecular sciences
Published: August 19, 2025
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.
Journal: Annals of hematology
Published: March 26, 2025
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Journal: Cancers
Published: January 21, 2024
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia.
Journal: Hematological oncology
Published: October 03, 2022
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 17, 2022
Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.
Journal: Journal for immunotherapy of cancer
Published: June 02, 2021
Last Updated: 09/26/2026